WO2005077897A1 - Substituted azetidine compounds, their preparation and use as medicaments - Google Patents
Substituted azetidine compounds, their preparation and use as medicaments Download PDFInfo
- Publication number
- WO2005077897A1 WO2005077897A1 PCT/EP2005/001658 EP2005001658W WO2005077897A1 WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1 EP 2005001658 W EP2005001658 W EP 2005001658W WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally
- substituted
- mono
- linear
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 150000001539 azetidines Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 24
- -1 mono-substituted phenyl group Chemical group 0.000 claims description 241
- 125000001424 substituent group Chemical group 0.000 claims description 156
- 229910052801 chlorine Inorganic materials 0.000 claims description 154
- 229910052731 fluorine Inorganic materials 0.000 claims description 137
- 125000000217 alkyl group Chemical group 0.000 claims description 135
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 129
- 229910052794 bromium Inorganic materials 0.000 claims description 124
- 125000002950 monocyclic group Chemical class 0.000 claims description 124
- 229920006395 saturated elastomer Polymers 0.000 claims description 118
- 239000000460 chlorine Substances 0.000 claims description 115
- 125000001072 heteroaryl group Chemical group 0.000 claims description 114
- 125000003118 aryl group Chemical group 0.000 claims description 95
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 86
- 125000002947 alkylene group Chemical group 0.000 claims description 79
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 76
- 125000005842 heteroatom Chemical group 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 75
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 71
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 57
- 208000035475 disorder Diseases 0.000 claims description 57
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 53
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 51
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 47
- 125000001544 thienyl group Chemical class 0.000 claims description 44
- 125000002541 furyl group Chemical group 0.000 claims description 43
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000001153 fluoro group Chemical group F* 0.000 claims description 36
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 35
- 150000001204 N-oxides Chemical class 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 31
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 30
- 239000012429 reaction media Substances 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000001931 aliphatic group Chemical class 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims description 23
- 125000001624 naphthyl group Chemical group 0.000 claims description 23
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 22
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 21
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 21
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- 239000005864 Sulphur Chemical group 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 239000001301 oxygen Chemical group 0.000 claims description 20
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000002619 bicyclic group Chemical group 0.000 claims description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 18
- 238000011321 prophylaxis Methods 0.000 claims description 18
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims description 16
- 108050007331 Cannabinoid receptor Proteins 0.000 claims description 16
- 229930003827 cannabinoid Natural products 0.000 claims description 15
- 239000003557 cannabinoid Substances 0.000 claims description 15
- 208000011117 substance-related disease Diseases 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 206010013663 drug dependence Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 7
- 210000000748 cardiovascular system Anatomy 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 7
- 210000002345 respiratory system Anatomy 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000032841 Bulimia Diseases 0.000 claims description 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010012335 Dependence Diseases 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 5
- 208000022531 anorexia Diseases 0.000 claims description 5
- 206010061428 decreased appetite Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- 235000012631 food intake Nutrition 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000015879 Cerebellar disease Diseases 0.000 claims description 4
- 208000014094 Dystonic disease Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000001953 Hypotension Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010033664 Panic attack Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000003782 Raynaud disease Diseases 0.000 claims description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 208000011641 Spinocerebellar disease Diseases 0.000 claims description 4
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 231100000284 endotoxic Toxicity 0.000 claims description 4
- 230000002346 endotoxic effect Effects 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000036543 hypotension Effects 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 230000003533 narcotic effect Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 230000001850 reproductive effect Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 230000002784 sclerotic effect Effects 0.000 claims description 4
- 230000002992 thymic effect Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- BNBGRXOGPFOPLL-QRQCRPRQSA-N n-[(2r,3s)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluorobenzenesulfonamide Chemical compound C([C@@H]([C@H]1C)NS(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BNBGRXOGPFOPLL-QRQCRPRQSA-N 0.000 claims description 3
- BNBGRXOGPFOPLL-OYHNWAKOSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluorobenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BNBGRXOGPFOPLL-OYHNWAKOSA-N 0.000 claims description 3
- NMZREQPYUSVIIX-MEDUHNTESA-N (2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-amine Chemical compound C[C@H]1[C@H](N)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 NMZREQPYUSVIIX-MEDUHNTESA-N 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
- XODIKZYDMAHSPS-UPCLLVRISA-N 4-acetyl-n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]benzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(=CC=2)C(C)=O)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 XODIKZYDMAHSPS-UPCLLVRISA-N 0.000 claims description 2
- LFLSATHZMYYIAQ-UHFFFAOYSA-N 4-flourobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C=C1 LFLSATHZMYYIAQ-UHFFFAOYSA-N 0.000 claims description 2
- WVSYONICNIDYBE-UHFFFAOYSA-N 4-fluorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(F)C=C1 WVSYONICNIDYBE-UHFFFAOYSA-N 0.000 claims description 2
- LNLYQVGIHBTFKG-QMHKHESXSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 LNLYQVGIHBTFKG-QMHKHESXSA-N 0.000 claims description 2
- KBZYHQABKNEVJK-AVRWGWEMSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C2=C(N(N=C2)C=2C=CC=CC=2)C)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C2=C(N(N=C2)C=2C=CC=CC=2)C)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 KBZYHQABKNEVJK-AVRWGWEMSA-N 0.000 claims description 2
- AJQTYRCYYGKDJI-KSFYIVLOSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C=2C3=CC=CC=C3SC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C3=CC=CC=C3SC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 AJQTYRCYYGKDJI-KSFYIVLOSA-N 0.000 claims description 2
- NQQZSKNYXUNFLL-HFJWLAOPSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 NQQZSKNYXUNFLL-HFJWLAOPSA-N 0.000 claims description 2
- JNQMSYHAWDHJPA-WTYVLRPYSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 JNQMSYHAWDHJPA-WTYVLRPYSA-N 0.000 claims description 2
- DZKBBMVMJPRBKE-SCLBCKFNSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C=2N3C=CSC3=NC=2Cl)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2N3C=CSC3=NC=2Cl)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 DZKBBMVMJPRBKE-SCLBCKFNSA-N 0.000 claims description 2
- GKTDYNGGZFLUNK-WTYVLRPYSA-N C([C@H]([C@@H]1C)NS(=O)(=O)CCC=2C3=CC=CC=C3C=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)CCC=2C3=CC=CC=C3C=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 GKTDYNGGZFLUNK-WTYVLRPYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- OLELREMYQQFANK-VBKZILBWSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-2,1,3-benzothiadiazole-4-sulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C3=NSN=C3C=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 OLELREMYQQFANK-VBKZILBWSA-N 0.000 claims description 2
- RITBMBQQADQHAZ-MEDUHNTESA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C[C@H]1[C@H](NC(=O)C(F)(F)F)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 RITBMBQQADQHAZ-MEDUHNTESA-N 0.000 claims description 2
- BGBDNSFFONZWAD-RCDICMHDSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-3,5-difluorobenzamide Chemical compound C([C@H]([C@@H]1C)NC(=O)C=2C=C(F)C=C(F)C=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGBDNSFFONZWAD-RCDICMHDSA-N 0.000 claims description 2
- HJXUSRGNAFOFFM-HMILPKGGSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-(4-bromophenoxy)benzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(OC=3C=CC(Br)=CC=3)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 HJXUSRGNAFOFFM-HMILPKGGSA-N 0.000 claims description 2
- NGNVYVKNYJPDOF-AFJIDDCJSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluoro-n-[(4-fluorophenyl)methyl]benzenesulfonamide Chemical compound C([C@H]([C@@H]1C)N(CC=2C=CC(F)=CC=2)S(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 NGNVYVKNYJPDOF-AFJIDDCJSA-N 0.000 claims description 2
- OPNLETKMWVQXOA-QMHKHESXSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluoro-n-methylbenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)N(C)S(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 OPNLETKMWVQXOA-QMHKHESXSA-N 0.000 claims description 2
- HWECFSOUORLJIW-QMHKHESXSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluoro-n-methylsulfonylbenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)N(S(C)(=O)=O)S(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 HWECFSOUORLJIW-QMHKHESXSA-N 0.000 claims description 2
- WIGGIEDOQRQISD-AVRWGWEMSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluoro-n-propylbenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)N(CCC)S(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 WIGGIEDOQRQISD-AVRWGWEMSA-N 0.000 claims description 2
- SFXTXMOHUAZTJJ-QMHKHESXSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-methylsulfonylbenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(=CC=2)S(C)(=O)=O)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 SFXTXMOHUAZTJJ-QMHKHESXSA-N 0.000 claims description 2
- OWTBFARKWJWPTA-WTYVLRPYSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-phenoxybenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 OWTBFARKWJWPTA-WTYVLRPYSA-N 0.000 claims description 2
- BUKQKDHNFJMMEN-SDDQJFBMSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-n-(7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonamide Chemical compound C([C@H]([C@@H]1C)N(C23C(CC(CC2)C3(C)C)=O)S(C)(=O)=O)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BUKQKDHNFJMMEN-SDDQJFBMSA-N 0.000 claims description 2
- SAQXOYXLZPGDGO-GAJHUEQPSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-n-phenylmethanesulfonamide Chemical compound C([C@H]([C@@H]1C)N(C=2C=CC=CC=2)S(C)(=O)=O)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 SAQXOYXLZPGDGO-GAJHUEQPSA-N 0.000 claims description 2
- YZVQUUKBYFDMQY-MGPUTAFESA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]butane-1-sulfonamide Chemical compound C[C@H]1[C@H](NS(=O)(=O)CCCC)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 YZVQUUKBYFDMQY-MGPUTAFESA-N 0.000 claims description 2
- FBCPNMOKIIQGED-KSFYIVLOSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]cyclohexanecarboxamide Chemical compound C([C@H]([C@@H]1C)NC(=O)C2CCCCC2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 FBCPNMOKIIQGED-KSFYIVLOSA-N 0.000 claims description 2
- BSXLLFUSNQCWJP-UHFFFAOYSA-N thiophene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=CS1 BSXLLFUSNQCWJP-UHFFFAOYSA-N 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 206010043903 Tobacco abuse Diseases 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- PPZFWLBZGQWMEP-UHFFFAOYSA-N 1,3,5-trimethylpyrazole-4-sulfonic acid Chemical compound CC1=NN(C)C(C)=C1S(O)(=O)=O PPZFWLBZGQWMEP-UHFFFAOYSA-N 0.000 claims 1
- VHMPGAJRLKGKLQ-AVRWGWEMSA-N C([C@H]([C@@H]1C)NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 VHMPGAJRLKGKLQ-AVRWGWEMSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 208000009132 Catalepsy Diseases 0.000 description 10
- 206010047853 Waxy flexibility Diseases 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229960004132 diethyl ether Drugs 0.000 description 9
- 206010039897 Sedation Diseases 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 230000036280 sedation Effects 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000036592 analgesia Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- RVJIUWJMJDLQIP-XJKSGUPXSA-N (2s,3r)-1-benzhydryl-2-methylazetidin-3-ol Chemical compound C[C@H]1[C@H](O)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 RVJIUWJMJDLQIP-XJKSGUPXSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 5
- OILLHIQWPYRWOI-WMLDXEAASA-N [(2s,3r)-1-benzhydryl-2-methylazetidin-3-yl] methanesulfonate Chemical compound C[C@H]1[C@H](OS(C)(=O)=O)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OILLHIQWPYRWOI-WMLDXEAASA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940065144 cannabinoids Drugs 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CJCQBRZYAQTEOO-XJKSGUPXSA-N (2s,3r)-1-benzhydryl-2-methylazetidin-3-amine Chemical compound C[C@H]1[C@H](N)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CJCQBRZYAQTEOO-XJKSGUPXSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 4
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000002631 hypothermal effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- NMZREQPYUSVIIX-BZNIZROVSA-N (2r,3s)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-amine Chemical compound C[C@@H]1[C@@H](N)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 NMZREQPYUSVIIX-BZNIZROVSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229920001774 Perfluoroether Polymers 0.000 description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004292 cyclic ethers Chemical class 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- RITBMBQQADQHAZ-BZNIZROVSA-N n-[(2r,3s)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C[C@@H]1[C@@H](NC(=O)C(F)(F)F)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 RITBMBQQADQHAZ-BZNIZROVSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- LTVSBZFRNCOETR-UHFFFAOYSA-N 1-[bromo-(4-chlorophenyl)methyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1C(Br)C1=CC=C(Cl)C=C1 LTVSBZFRNCOETR-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- HRQHJTJCRMLNPP-OYHNWAKOSA-N [(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl] 4-fluorobenzenesulfonate Chemical compound C([C@H]([C@@H]1C)OS(=O)(=O)C=2C=CC(F)=CC=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 HRQHJTJCRMLNPP-OYHNWAKOSA-N 0.000 description 2
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- OKZNPPMXPUCIDX-UHFFFAOYSA-N (2-methylazetidin-3-yl) 2,2-dimethylpropanoate;hydrochloride Chemical compound Cl.CC1NCC1OC(=O)C(C)(C)C OKZNPPMXPUCIDX-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 0 *C(*)N1C(*)C(*)(*)C1 Chemical compound *C(*)N1C(*)C(*)(*)C1 0.000 description 1
- QRABWFYVCUFAAB-UHFFFAOYSA-N 1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-ol Chemical compound CC1C(O)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 QRABWFYVCUFAAB-UHFFFAOYSA-N 0.000 description 1
- AZHWVHNIAGJINK-UHFFFAOYSA-N 1-benzhydrylazetidine Chemical class C1CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AZHWVHNIAGJINK-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical group CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- LOHMOYDNSULEAJ-DMTCNVIQSA-N 2,2,2-trifluoro-n-[(2r,3s)-2-methylazetidin-3-yl]acetamide Chemical compound C[C@H]1NC[C@@H]1NC(=O)C(F)(F)F LOHMOYDNSULEAJ-DMTCNVIQSA-N 0.000 description 1
- LOHMOYDNSULEAJ-IUYQGCFVSA-N 2,2,2-trifluoro-n-[(2s,3r)-2-methylazetidin-3-yl]acetamide Chemical compound C[C@@H]1NC[C@H]1NC(=O)C(F)(F)F LOHMOYDNSULEAJ-IUYQGCFVSA-N 0.000 description 1
- RZUXIYDMQGCCDD-UHFFFAOYSA-N 2,3-dibromobutan-1-ol Chemical compound CC(Br)C(Br)CO RZUXIYDMQGCCDD-UHFFFAOYSA-N 0.000 description 1
- CPZUINYGJOGDQX-UHFFFAOYSA-N 2-[(3-chlorophenyl)-imidazol-1-ylmethyl]adamantan-2-ol Chemical compound C1C2CC(C3)CC1CC3C2(O)C(N1C=NC=C1)C1=CC=CC(Cl)=C1 CPZUINYGJOGDQX-UHFFFAOYSA-N 0.000 description 1
- MRHUWANOQDXKAG-WMLDXEAASA-N 3-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-2,2-dimethylpropanoic acid Chemical compound C[C@H]1[C@H](CC(C)(C)C(O)=O)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 MRHUWANOQDXKAG-WMLDXEAASA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PHUYGURFBULKPA-UHFFFAOYSA-N 4,4'-dichlorobenzhydrol Chemical compound C=1C=C(Cl)C=CC=1C(O)C1=CC=C(Cl)C=C1 PHUYGURFBULKPA-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKZNPPMXPUCIDX-UOERWJHTSA-N Cl.C[C@@H]1NC[C@H]1OC(=O)C(C)(C)C Chemical compound Cl.C[C@@H]1NC[C@H]1OC(=O)C(C)(C)C OKZNPPMXPUCIDX-UOERWJHTSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920003776 Reny® Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
- NRJVSTWYKYKNBK-QFBILLFUSA-N [(2s,3r)-1-benzhydryl-2-methylazetidin-3-yl] 2,2-dimethylpropanoate Chemical compound C[C@H]1[C@H](OC(=O)C(C)(C)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NRJVSTWYKYKNBK-QFBILLFUSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical class OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- XEBCWEDRGPSHQH-UHFFFAOYSA-N diisopropyl tartrate Chemical compound CC(C)OC(=O)C(O)C(O)C(=O)OC(C)C XEBCWEDRGPSHQH-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PGQDAWJAYJIGTH-RCDICMHDSA-N n-[(2s,3r)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-3,5-dichlorobenzenesulfonamide Chemical compound C([C@H]([C@@H]1C)NS(=O)(=O)C=2C=C(Cl)C=C(Cl)C=2)N1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 PGQDAWJAYJIGTH-RCDICMHDSA-N 0.000 description 1
- SCKIGOBSACJIRK-XJKSGUPXSA-N n-[(2s,3r)-1-benzhydryl-2-methylazetidin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C[C@H]1[C@H](NC(=O)C(F)(F)F)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 SCKIGOBSACJIRK-XJKSGUPXSA-N 0.000 description 1
- ZKNYVNQXGPDKFH-MELYUZJYSA-N n-[(2s,3r)-1-benzhydryl-2-methylazetidin-3-yl]-2,2,2-trifluoroacetamide;hydrochloride Chemical compound Cl.C[C@H]1[C@H](NC(=O)C(F)(F)F)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 ZKNYVNQXGPDKFH-MELYUZJYSA-N 0.000 description 1
- WBIYZICLJFECRW-UHFFFAOYSA-N n-[1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]hexanamide Chemical compound CC1C(NC(=O)CCCCC)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 WBIYZICLJFECRW-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0507801-6A BRPI0507801A (pt) | 2004-02-17 | 2005-02-16 | compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda |
| RU2006133258/04A RU2006133258A (ru) | 2004-02-17 | 2005-02-16 | Замещенные азетидиновые производные, их получение и применение в качестве лекарственных средств |
| JP2006553539A JP2007522255A (ja) | 2004-02-17 | 2005-02-16 | 置換アゼチジン化合物、その製造および医薬品としての使用 |
| EP05715383A EP1718609A1 (de) | 2004-02-17 | 2005-02-16 | Substituierte azetidinverbindungen, deren herstellung und deren verwendung als medikamente |
| AU2005212835A AU2005212835A1 (en) | 2004-02-17 | 2005-02-16 | Substituted Azetidine compounds, their preparation and use as medicaments |
| CA002556565A CA2556565A1 (en) | 2004-02-17 | 2005-02-16 | Substituted azetidine compounds, their preparation and use as medicaments |
| IL177456A IL177456A0 (en) | 2004-02-17 | 2006-08-10 | Substituted azetidine compounds, their preparation and use as medicaments |
| US11/505,463 US20070066587A1 (en) | 2004-02-17 | 2006-08-17 | Substituted azetidine compounds, their preparation and use as medicaments |
| NO20064078A NO20064078L (no) | 2004-02-17 | 2006-09-11 | Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200400379A ES2244314B1 (es) | 2004-02-17 | 2004-02-17 | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos. |
| ES200400379 | 2004-02-17 | ||
| US10/804,558 | 2004-03-19 | ||
| US10/804,558 US20050187208A1 (en) | 2004-02-17 | 2004-03-19 | Substituted Azetidine compounds, their preparation and use as medicaments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/505,463 Continuation-In-Part US20070066587A1 (en) | 2004-02-17 | 2006-08-17 | Substituted azetidine compounds, their preparation and use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005077897A1 true WO2005077897A1 (en) | 2005-08-25 |
Family
ID=34863169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/001658 WO2005077897A1 (en) | 2004-02-17 | 2005-02-16 | Substituted azetidine compounds, their preparation and use as medicaments |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1718609A1 (de) |
| JP (1) | JP2007522255A (de) |
| KR (1) | KR20060124756A (de) |
| AU (1) | AU2005212835A1 (de) |
| BR (1) | BRPI0507801A (de) |
| CA (1) | CA2556565A1 (de) |
| NO (1) | NO20064078L (de) |
| RU (1) | RU2006133258A (de) |
| WO (1) | WO2005077897A1 (de) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007169270A (ja) * | 2005-11-25 | 2007-07-05 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US7485732B2 (en) | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| FR2928149A1 (fr) * | 2008-02-29 | 2009-09-04 | Sanofi Aventis Sa | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| FR2946650A1 (fr) * | 2009-06-16 | 2010-12-17 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
| WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013001505A3 (en) * | 2011-06-29 | 2013-03-07 | Adamed Sp. Z O.O. | Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases |
| EP2754653A2 (de) * | 2011-09-05 | 2014-07-16 | Korea Institute of Science and Technology | Azetidinderivat und antidepressive zusammensetzung damit |
| US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0406112A1 (de) * | 1989-06-29 | 1991-01-02 | Laboratorios Del Dr. Esteve, S.A. | 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung |
| WO2001064633A1 (fr) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
| WO2003020314A1 (fr) * | 2001-08-29 | 2003-03-13 | Aventis Pharma S.A. | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau |
| WO2003053431A2 (fr) | 2001-12-21 | 2003-07-03 | Aventis Pharma S.A. | Compositions pharmaceutiques a base de derives d'azetidine |
-
2005
- 2005-02-16 RU RU2006133258/04A patent/RU2006133258A/ru unknown
- 2005-02-16 KR KR1020067018702A patent/KR20060124756A/ko not_active Application Discontinuation
- 2005-02-16 EP EP05715383A patent/EP1718609A1/de not_active Withdrawn
- 2005-02-16 CA CA002556565A patent/CA2556565A1/en not_active Abandoned
- 2005-02-16 JP JP2006553539A patent/JP2007522255A/ja not_active Withdrawn
- 2005-02-16 AU AU2005212835A patent/AU2005212835A1/en not_active Abandoned
- 2005-02-16 WO PCT/EP2005/001658 patent/WO2005077897A1/en active Application Filing
- 2005-02-16 BR BRPI0507801-6A patent/BRPI0507801A/pt not_active Application Discontinuation
-
2006
- 2006-09-11 NO NO20064078A patent/NO20064078L/no not_active Application Discontinuation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0406112A1 (de) * | 1989-06-29 | 1991-01-02 | Laboratorios Del Dr. Esteve, S.A. | 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung |
| US5073646A (en) | 1989-06-29 | 1991-12-17 | Laboratorios Del Dr. Esteve, S.A. | Substituted 1-diphenylmethyl azetidines |
| WO2001064633A1 (fr) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
| WO2003020314A1 (fr) * | 2001-08-29 | 2003-03-13 | Aventis Pharma S.A. | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau |
| WO2003053431A2 (fr) | 2001-12-21 | 2003-07-03 | Aventis Pharma S.A. | Compositions pharmaceutiques a base de derives d'azetidine |
Non-Patent Citations (47)
| Title |
|---|
| A. C. HOWLETT ET AL.: "International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors", PHARMACOL REV, vol. 54, 2002, pages 161 - 202 |
| A. SASSE ET AL., ARCH. PHARM., vol. 334, no. 2, 2001, pages 45 - 52 |
| ALPERMANN H. G. ET AL.: "Pharmacological effets of Hoe 249: A new potential antidepressant", DRUGS DEV. RES., vol. 25, 1992, pages 267 - 282 |
| AXENROD ET AL., TETRAHEDRON LETT., 1993, pages 6677 - 6680 |
| BARUAH ET AL., SYNLETT, no. 4, 1999, pages 409 - 410 |
| BULL. SOC. CHIM. FRANCE, vol. 132, no. 5-6, 1995, pages 522 - 30 |
| CATALYSIS LETTERS, vol. 62, no. 2-4, 1999, pages 175 - 177 |
| CHEM. BER., vol. 123, no. 12, 1990, pages 2387 - 94 |
| CONSROE; SANDYK: "Neurobiology and Neurophysiology", vol. 459, 1992, CRC PRESS, article "Marijuana/Cannabinoids" |
| DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) :Inhibition of Tetrahvdrocannbinol- induced Responses and Apparent Aaonist Activity", J. PHARMACOL. EXP. THER., vol. 277, no. 2, 1996, pages 586 - 594 |
| DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) Inhibition of Tetrahydrocannbinol- induced Responses and Apparent Agonist Activity", J. PHARMACOL EXP THER., vol. 277, no. 2, 1996, pages 586 - 594 |
| DEJAEGHER ET AL., SYNLETT., 2002, pages 113 - 115 |
| DESMET L. K. C. ET AL.: "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", ARZNEIM. -FORSCH. (FRUG RES), vol. 25, 1975, pages 9 |
| FARMACO, vol. 44, no. 12, 1989, pages 1167 - 91 |
| FERNANDEZ ET AL., SYNTHESIS, no. 2, 2001, pages 239 - 242 |
| FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 2. Synthesis and Biological Activity of 7-(2,3-Disubstituted-1-azetidinyl)-4-oxoquino line- and -1,8-naphthyridine-3-carboxylic Acids. Properties and Structure-Activity Relationships of Quinolones with an Azetidine Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 24, 1994, pages 4195 - 4210, XP002115349, ISSN: 0022-2623 * |
| FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 3. Synthesis, Properties and Structure-Activity Relationships of the Stereoisomers Containing a 7-(3-Amino-2-methyl-1-azetidinyl) Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 7, 1995, pages 1203 - 1215, XP002115345, ISSN: 0022-2623 * |
| HAJIPOUR ET AL., SYNTH. COMMUN., vol. 29, no. 10, 1999, pages 1697 - 1701 |
| HETEROCYCLES, vol. 32, no. 5, 1991, pages 965 - 73 |
| HIGGINS ET AL., J. HETEROCYCLIC CHEM., vol. 8, 1971, pages 1059 - 1062 |
| HOLLISTER, PHARM. REV., vol. 38, 1986, pages 1 - 20 |
| J. A. MARSHALL ET AL., ORG. LETT., vol. 2, no. 18, 2000, pages 2897 - 2900 |
| J. AM. CHEM. SOC., 2001, pages 12168 - 12175 |
| J. AM. CHEM. SOC., vol. 111, no. 9, 1989, pages 3363 - 3368 |
| J. FRIGOLA ET AL., J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215 |
| J. FRIGOLA, J. MED. CHEM., vol. 36, 1993, pages 801 - 810 |
| J. FRIGOLA, J. MED. CHEM., vol. 37, 1994, pages 4195 - 4210 |
| J. FRIGOLA, J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215 |
| J. MED. CHEM., vol. 33, no. 3, 1990, pages 908 - 18 |
| J. NATURAL PRODUCTS, vol. 65, no. 6, 2002, pages 902 - 908 |
| J. ORG. CHEM., vol. 63, no. 25, 1998, pages 9565 - 68 |
| J. ORG. CHEM., vol. 64, no. 7, 1999, pages 2582 - 2589 |
| KATRITZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275 |
| KATRIZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275 |
| M. GRISAR ET AL., J. MED. CHEM., 1973, pages 885 |
| M.E. JUNG, J. ORG. CHEM., vol. 56, no. 24, 1991, pages 6729 - 6730 |
| P.R. DAVE ET AL., J. ORG. CHEM., vol. 61, no. 16, 1996, pages 5453 |
| RENY; SINGHA, PROG. DRUG. RES., vol. 36, 1991, pages 71 - 114 |
| RUTH A. ROSS; HEATHER C. BROCKIE ET AL.: "Agonist-inverse agonist characterization at CB and CB2 cannabinoid receptors of L-759633, L759656 and AM630", BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, 1999, pages 665 - 672 |
| SHARPLESS ET AL., J. AM. CHEM. SOC., vol. 102, 1980, pages 5974 - 5976 |
| SYNLETT., 1991, pages 783 - 784 |
| SYNLETT., 1999, pages 1763 - 65 |
| SYNTHESIS, vol. 8, 1989, pages 598 - 603 |
| TETRAHEDRON LETT., vol. 43, no. 49, 2002, pages 8893 - 8896 |
| TETRAHEDRON, vol. 40, no. 7, 1984, pages 1195 - 1198 |
| V.R. GAERTNER, J. ORG. CHEM., vol. 32, 1967, pages 2972 |
| WOOLFE D. ET AL.: "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. PHARMACOL. EXP. THER., vol. 80, 1944, pages 300 - 307 |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485732B2 (en) | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| US7906503B2 (en) | 2003-06-11 | 2011-03-15 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| JP2007169270A (ja) * | 2005-11-25 | 2007-07-05 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO2009118473A3 (fr) * | 2008-02-29 | 2009-11-19 | Sanofi-Aventis | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique |
| WO2009118473A2 (fr) | 2008-02-29 | 2009-10-01 | Sanofi-Aventis | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique |
| FR2928149A1 (fr) * | 2008-02-29 | 2009-09-04 | Sanofi Aventis Sa | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| FR2946650A1 (fr) * | 2009-06-16 | 2010-12-17 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
| WO2010146299A1 (fr) * | 2009-06-16 | 2010-12-23 | Sanofi-Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique comme modulateurs des recepteurs cannabinoides |
| WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013001505A3 (en) * | 2011-06-29 | 2013-03-07 | Adamed Sp. Z O.O. | Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases |
| EP2754653A2 (de) * | 2011-09-05 | 2014-07-16 | Korea Institute of Science and Technology | Azetidinderivat und antidepressive zusammensetzung damit |
| EP2754653A4 (de) * | 2011-09-05 | 2015-02-18 | Korea Inst Sci & Tech | Azetidinderivat und antidepressive zusammensetzung damit |
| US9120771B2 (en) | 2011-09-05 | 2015-09-01 | Korea Institute Of Science And Technology | Azetidine derivative and antidepressant composition including the same |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1718609A1 (de) | 2006-11-08 |
| JP2007522255A (ja) | 2007-08-09 |
| CA2556565A1 (en) | 2005-08-25 |
| KR20060124756A (ko) | 2006-12-05 |
| BRPI0507801A (pt) | 2007-07-10 |
| RU2006133258A (ru) | 2008-04-10 |
| AU2005212835A1 (en) | 2005-08-25 |
| NO20064078L (no) | 2006-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005077897A1 (en) | Substituted azetidine compounds, their preparation and use as medicaments | |
| US7524868B2 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| UA73554C2 (en) | A pharmaceutical composition containing azetidine derivatives, azetidine derivatives and preparation thereof | |
| US20070066587A1 (en) | Substituted azetidine compounds, their preparation and use as medicaments | |
| EP1757587A1 (de) | Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel | |
| EP1743890A1 (de) | 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente. | |
| EP1844031A1 (de) | Substituierte phenylpiperazinverbindungen, ihre herstellung und verwendung in medikamenten | |
| JP2008525388A (ja) | カンナビノイドｃｂ１受容体アンタゴニストとしてのｎ−［（４，５−ジフェニル−３−アルキル−２−チエニル）メチル］アミン（アミド、スルホンアミド、カルバミン酸及び尿素）誘導体 | |
| WO2007017124A1 (en) | Amorphous phase of a substituted pyrazoline, its preparation and use as medicament | |
| WO2007009705A1 (en) | (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates | |
| WO2007017126A2 (en) | POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR | |
| EP1743892A1 (de) | Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament | |
| EP1743888A1 (de) | Carbonyl-substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren | |
| US7790727B2 (en) | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | |
| JP2008088057A (ja) | Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体 | |
| EP1743894A1 (de) | Heterocyclyl-substituierte Pyrazolinverbindungen, ihre Herstellung und Verwendung als Medikamente | |
| MXPA06009336A (es) | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos | |
| US20090149472A1 (en) | Salts of substitutted pyrazoline compounds, their preparation and use and medicaments | |
| MX2011001669A (es) | Compuestos polisustituidos de azetidinas, su preparacion y su aplicacion en terapeutica. | |
| EP1749821A1 (de) | Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel | |
| MXPA06009334A (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| EP1743887A1 (de) | Thiocarbonyl-Substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 177456 Country of ref document: IL Ref document number: 4609/DELNP/2006 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006/06732 Country of ref document: ZA Ref document number: 200606732 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2556565 Country of ref document: CA Ref document number: PA/a/2006/009336 Country of ref document: MX Ref document number: 549201 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006553539 Country of ref document: JP Ref document number: 11505463 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005212835 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005715383 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2005212835 Country of ref document: AU Date of ref document: 20050216 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005212835 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020067018702 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006133258 Country of ref document: RU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200580011514.6 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005715383 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020067018702 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 11505463 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: PI0507801 Country of ref document: BR |